{"id":18166,"date":"2023-06-01T22:34:00","date_gmt":"2023-06-01T14:34:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18166"},"modified":"2024-12-15T22:38:07","modified_gmt":"2024-12-15T14:38:07","slug":"antengenes-xpovio-combination-therapy-approved-for-reimbursement-in-australia-for-r-r-mm","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18166","title":{"rendered":"Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM"},"content":{"rendered":"\n

China-based biotech Antengene Corp., Ltd (HKG: 6996<\/a>) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm\u2019s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed\/refractory multiple myeloma (R\/R MM), specifically for those who have previously received one other therapy. This marks an expansion of coverage, as Xpovio plus dexamethasone was previously granted reimbursement for R\/R MM.<\/p>\n\n\n\n

Xpovio: The First and Only Oral XPO1 Inhibitor<\/strong>
Discovered by US-based Karyopharm Therapeutics Inc. (NASDAQ: KPTI<\/a>), Xpovio is the world’s first and only FDA-approved oral XPO1 inhibitor, used to treat hematological malignancies. Karyopharm licensed the rights for the drug to Antengene in Greater China, South Korea, and ASEAN countries in May 2018. The drug received its first approval in the US to treat R\/R MM and R\/R DLBCL in 2019, followed by conditional approval in China in November 2021. It has since gained market approval in Singapore and Australia in March 2022.<\/p>\n\n\n\n

Broadening Access to Xpovio for Patients with R\/R MM<\/strong>
The inclusion of Xpovio in the Australian PBS is a significant step forward in broadening access to this innovative treatment for patients with R\/R MM. The reimbursement coverage will help reduce the financial burden on patients and improve the affordability of this potentially life-changing therapy.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS)…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[136,30,91,16,29,926,418,927],"class_list":["post-18166","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-antengene","tag-biotech","tag-boao-lecheng-pilot-zone","tag-cancer","tag-combination-therapy","tag-hkg-6996","tag-karyopharm-therapeutics","tag-nasdaq-kpti"],"yoast_head":"\nAntengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm\u2019s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed\/refractory multiple myeloma (R\/R MM), specifically for those who have previously received one other therapy. This marks an expansion of coverage, as Xpovio plus dexamethasone was previously granted reimbursement for R\/R MM.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18166\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18166\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-01T14:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-15T14:38:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R\\\/R MM\",\"datePublished\":\"2023-06-01T14:34:00+00:00\",\"dateModified\":\"2024-12-15T14:38:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Antengene\",\"Biotech\",\"Boao Lecheng pilot zone\",\"Cancer\",\"Combination therapy\",\"HKG: 6996\",\"Karyopharm Therapeutics\",\"NASDAQ: KPTI\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18166#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18166\",\"name\":\"Antengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\\\/R MM - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-01T14:34:00+00:00\",\"dateModified\":\"2024-12-15T14:38:07+00:00\",\"description\":\"China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm\u2019s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed\\\/refractory multiple myeloma (R\\\/R MM), specifically for those who have previously received one other therapy. This marks an expansion of coverage, as Xpovio plus dexamethasone was previously granted reimbursement for R\\\/R MM.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18166\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18166#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R\\\/R MM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM - Insight, China's Pharmaceutical Industry","description":"China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm\u2019s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed\/refractory multiple myeloma (R\/R MM), specifically for those who have previously received one other therapy. This marks an expansion of coverage, as Xpovio plus dexamethasone was previously granted reimbursement for R\/R MM.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18166","og_locale":"en_US","og_type":"article","og_title":"Antengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18166","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-01T14:34:00+00:00","article_modified_time":"2024-12-15T14:38:07+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18166#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18166"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM","datePublished":"2023-06-01T14:34:00+00:00","dateModified":"2024-12-15T14:38:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18166"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Antengene","Biotech","Boao Lecheng pilot zone","Cancer","Combination therapy","HKG: 6996","Karyopharm Therapeutics","NASDAQ: KPTI"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18166#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18166","url":"https:\/\/flcube.com\/?p=18166","name":"Antengene's Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-01T14:34:00+00:00","dateModified":"2024-12-15T14:38:07+00:00","description":"China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia\u2019s Pharmaceutical Benefits Scheme (PBS) will reimburse the firm\u2019s Xpovio (selinexor) plus bortezomib and dexamethasone combination therapy for the treatment of adult patients with relapsed\/refractory multiple myeloma (R\/R MM), specifically for those who have previously received one other therapy. This marks an expansion of coverage, as Xpovio plus dexamethasone was previously granted reimbursement for R\/R MM.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18166#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18166"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18166#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R\/R MM"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18166"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18166\/revisions"}],"predecessor-version":[{"id":18167,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18166\/revisions\/18167"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}